Trial: 201810124

A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Phase

I

Principal Investigator

Schroeder, Mark

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov